Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRS Study of Concerta in ADHD Youth
NCT00593112Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2006
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Glutamate/myo-Inositol ratio at 6 weeks, Glutamine/myo-Inositol ratio at 6 weeks and 1 more. Started Nov 2006; status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00593112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00593112.